CoChat

Characterization of a Novel PERK Kinase Inhibitor with Antitumor and Antiangiogenic Activity

Published version of a preprint

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Abstract

The unfolded protein response (UPR) is a signal transduction pathway that coordinates cellular adaptation to microenvironmental stresses that include hypoxia, nutrient deprivation, and change in redox status. These stress stimuli are common in many tumors and thus targeting components of the UPR signaling is an attractive therapeutic approach. We have identified a first-in-class, small molecule inhibitor of the eukaryotic initiation factor 2-alpha kinase 3 (EIF2AK3) or PERK, one of the three mediators of UPR signaling. GSK2656157 is an ATP-competitive inhibitor of PERK enzyme activity with an IC(50) of 0.9 nmol/L. It is highly selective for PERK with IC(50) values >100 nmol/L against a panel of 300 kinases. GSK2656157 inhibits PERK activity in cells with an IC(50) in the range of 10-30 nmol/L as shown by inhibition of stress-induced PERK autophosphorylation, eIF2α substrate phosphorylation, together with corresponding decreases in ATF4 and CAAT/enhancer binding protein homologous protein (CHOP) in multiple cell lines. Oral administration of GSK2656157 to mice shows a dose- and time-dependent pharmacodynamic response in pancreas as measured by PERK autophosphorylation. Twice daily dosing of GSK2656157 results in dose-dependent inhibition of multiple human tumor xenografts growth in mice. Altered amino acid metabolism, decreased blood vessel density, and vascular perfusion are potential mechanisms for the observed antitumor effect. However, despite its antitumor activity, given the on-target pharmacologic effects of PERK inhibition on pancreatic function, development of any PERK inhibitor in human subjects would need to be cautiously pursued in cancer patients.

Overview

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-12-3109

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 44 references

Research works printed but not linked: 1

  1. Gales, 2012, PERK inhibitor induces pancreatic toxicity in rats, Soc Tox Path

Cited by

See all 444

Metadata

Authors
Atkins, C., Liu, Q., Minthorn, E., Zhang, S.-Y., Figueroa, D. J., Moss, K., Stanley, T. B., Sanders, B., Goetz, A., Gaul, N., Choudhry, A. E., Alsaid, H., Jucker, B. M., Axten, J. M., & Kumar, R.
Affiliations
  • GlaxoSmithKline (United States) (US)
  • Authors' Affiliations: 1GlaxoSmithKline, Oncology R&D; 2Platform Technology & Science, Collegeville, Pennsylvania; 3Platform Technology & Science, Research Triangle Park, North Carolina; and 4Preclinical and Translational Imaging, LAS, King of Prussia, Pennsylvania
Venue
Cancer Research
Published
2013-03-14
Volume
73
Issue
6
Pages
1993-2002
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W1991250346
Cited by
443
References
44
Citations by year
2026: 16 · 2025: 25 · 2024: 27 · 2023: 29 · 2022: 36 · 2021: 36 · 2020: 47 · 2019: 43 · 2018: 40 · 2017: 34 · 2016: 29 · 2015: 34 · 2014: 32 · 2013: 14
FWCI
21.26
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Endoplasmic Reticulum Stress and Disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Keywords
GSK2656157, unfolded protein response, PERK, eIF2α phosphorylation, ATF4, CHOP, anticancer activity, antiangiogenic activity, tumor xenografts, pancreatic function, amino acid metabolism, blood vessel density, vascular perfusion, kinase selectivity
MeSH terms
Adenine, Animals, Antineoplastic Agents, Female, Indoles, eIF-2 Kinase, Angiogenesis Inhibitors, Gene Expression Profiling, Protein Kinase Inhibitors, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Characterization of a Novel PERK Kinase Inhibitor with Antitumor and Antiangiogenic Activity. https://app.cochat.ai/papers/10.1158/0008-5472.can-12-3109
The paper
Atkins, C., Liu, Q., Minthorn, E., Zhang, S.-Y., Figueroa, D. J., Moss, K., Stanley, T. B., Sanders, B., Goetz, A., Gaul, N., Choudhry, A. E., Alsaid, H., Jucker, B. M., Axten, J. M., & Kumar, R. (2013). Characterization of a Novel PERK Kinase Inhibitor with Antitumor and Antiangiogenic Activity. Cancer Research. https://doi.org/10.1158/0008-5472.can-12-3109

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.